|Slideshows|March 4, 2021

7 Things to Know About Parasomnias

Author(s)Thomas D. Hurwitz, MD, Carlos H. Schenck, MD, Imran S. Khawaja, MBBS

Nightmare disorder can produce emotional manifestations of fear, anger, and sadness. Here are 7 reasons parasomnias can challenge even the most astute diagnostician.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Stuttering, A Misunderstood Condition: What the Field of Neuropsychiatry Can Do to Help

ByGerald A. Maguire, MD

November 25th 2025

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

ByGarrett Rossi, MD

November 25th 2025

Tonmya Available Commercially for Treatment of Fibromyalgia

ByJessica Walters

November 18th 2025

Alixorexton for Treatment of Narcolepsy Type 2: New Positive Phase 2 Data

ByLeah Kuntz

November 13th 2025

Beyond Survival: Understanding the Long Road to Stroke Recovery

ByMatthew Ashley, MD, JD

October 29th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

7 Things to Know About Parasomnias

Newsletter

Related Content

Stuttering, A Misunderstood Condition: What the Field of Neuropsychiatry Can Do to Help

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

Tonmya Available Commercially for Treatment of Fibromyalgia

Alixorexton for Treatment of Narcolepsy Type 2: New Positive Phase 2 Data

Beyond Survival: Understanding the Long Road to Stroke Recovery

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

What Happened to Psychopathology?

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Catatonia Crisis: Navigating the IV Lorazepam Shortage